✣OncoGonFROM DISCOVERY TO IMPACT
HomeAssetsTriage & Prioritisation
3D Tumour IntelligenceExperimentsImagingSegmentation & QCResponse AnalysisAI Analysis (OSIEL)
Qualified AssetsIndustry & Data RoomCollaborationReports & Insights
Admin
Home
RESEARCH PORTFOLIO

Good morning, Dr. Mokoena

Here’s what’s happening across your oncology research portfolio.

Services operational
Active Assets245+12% this month
Active 3D Studies184 requiring review
Qualified Assets36+5 this quarter
Industry Engagements123 active diligence

Featured 3D Study

Latest high-priority response study

Open Study
Tumour spheroid representation
BC-001

Breast Cancer Spheroid Response Study

Breast Cancer | TNBC, HER2-

Ready for reviewResponse Analysis
Lead scientistDr. S. Mokoena
TreatmentsControl · Drug A · Drug B
Current timepointDay 7
Latest responseDrug B — Strong ResponseStudy record · requires scientific review
Tumour size-71%
Viability18%
Study progress · confidence 0.9272%
Open Study View Response Analysis

Asset Pipeline

Portfolio progression from discovery to partner readiness

View assets
01245Identified0272Triage0348Validation0436Qualification0518Industry Ready
Screening conversion29%
Qualified for next stage15%
Discovery Validation Commercial

Recent Assets

Candidates with recent portfolio activity

View library
AssetModality / IndicationStageOwnerUpdated
OGC-2401Novel small moleculeSmall MoleculeBreast CancerIn 3D StudySMDr. S. Mokoena10-03
OGC-BC-118Selective inhibitorBiologicBreast CancerIn ScreeningJPDr. J. Patel10-02
OGC-NS-321CNS penetrant agentSmall MoleculeGlioblastomaIn 3D StudyMRDr. M. Rossi09-27
OGC-LU-104Targeted degraderPROTACLung CancerIn ScreeningAKDr. A. Kumar09-25

Upcoming Activities

Research and review schedule

08Oct
Scientific review due09:30 · Scientific Review Board · OGC-2401
Due soon
09Oct
3D imaging session11:00 · Imaging Core · BC-001
Scheduled
10Oct
Evidence package review14:00 · Dr. J. Patel · OGC-BC-118
In review
13Oct
Dataset eligibility review10:00 · Data Governance · DS-2401-04
Scheduled
15Oct
TTO qualification meeting15:30 · TTO Team · OGC-2401
Scheduled

OSIEL AI Insights

Research intelligence · human review required

3 high-confidence candidates identifiedIllustrative portfolio signal; scientific review required.
2 evidence gaps require reviewReplication and pathway evidence remain incomplete.
OGC-2401 has strong 3D-response evidenceReview linked study BC-001 before progression.
OGC-BC-118 may benefit from pathway evidenceSuggested for researcher assessment.
Open OSIELView Recommendations

Industry Engagements

Current partner discussions

Open data room
Pharma Partner AOGC-2401 · 2 days ago
DiligenceN. Adams
Biotech Partner BOGC-NS-321 · 5 days ago
Scientific DiscussionT. Jacobs
Research Partner COGC-LU-104 · 1 week ago
Sponsored ValidationN. Daniels

Research Notifications

System and portfolio updates

3D results ready for reviewBC-001 · 2h ago
New dataset linked to OGC-2401DS-2401-12 · 5h ago
Scientific reviewer requested correctionOGC-IM-009 · Yesterday
Evidence package approvedOGC-OV-207 · Yesterday
Industry access request pendingPharma Partner A · 2d ago